Debacterol is a topical pharmaceutical that is used in the treatment of ulcerating oral mucosal lesions (canker sores). It has also been successfully used in clinical settings for gingival and medium to severe periodontitis.
Oral Medicine treatment for oral mucosal disease, orofacial pain and headache, temporomandibular disorders known as TMJ and dental appliances for treatment of snoring and sleep apnoea in Melbourne
MIVAC Development is a biopharmaceutical company focused on discovery, development and commercialisation of novel treatments of autoimmune diseases, antiallergic therapies, treatments against Alzheimer’s Disease and mucosal vaccine development.
People with inflammatory bowel disease have a damaged mucosal lining, and their intestinal tract is often riddled with ulcers, fissures, inflamed patches and even fistulas.
Debacterol is a topical pharmaceutical that is used in the treatment of ulcerating oral mucosal lesions (canker sores). It has also been successfully used in clinical settings for gingival and medium to severe periodontitis.
MIVAC Development is a biopharmaceutical company focused on discovery, development and commercialisation of novel treatments of autoimmune diseases, antiallergic therapies, treatments against Alzheimer’s Disease and mucosal vaccine development.
MIVAC Development is a biopharmaceutical company focused on discovery, development and commercialisation of novel treatments of autoimmune diseases, antiallergic therapies, treatments against Alzheimer’s Disease and mucosal vaccine development.
MIVAC Development is a biopharmaceutical company focused on discovery, development and commercialisation of novel treatments of autoimmune diseases, antiallergic therapies, treatments against Alzheimer’s Disease and mucosal vaccine development.